Related Results

CIPROCiproCIPROCIPROCIPRO

* Special Considerations: Although ciprofloxacin was effective in clinical trials, it is not a first-line treatment for pediatric patients. In studies, there was an increased incidence of adverse events compared with controls, including joint and surrounding tissue effects that included arthralgia, abnormal gait, joint sprains, myalgia, and bone pain.
Ciprofloxacin should only be used for the FDA-approved indications in pediatric patients, according to the labeling.
* Comment: Researchers in clinical trials compared 337 pediatric patients taking intravenous and/or oral ciprofloxacin with 352 patients taking a cephalosporin for complicated UTIs or pyelonephritis. The mean age was 6 years, and mean duration of therapy was 11 days. The ciprofloxacin group experienced a 95.7% clinical response, vs. 92.6% for the cephalosporin group at 5-9 days post treatment. Also, 84.4% of the ciprofloxacin group experienced bacteriologic eradication, compared with 78.3% of the cephalosporin group.
“This approval signals a major change in the status of ciprofloxacin and other quinolones. Historically, this class of antibiotics has not been approved in children due to concerns about arthropathies, which have occurred in all animal species tested,” Dr. John V. Williams of the department of pediatric infectious diseases at Vanderbilt Children’s Hospital, Nashville, Tenn., said in an interview. “This approval opens the door to new, wider use of a potent class of antimicrobials in children, with the potential attendant risks and benefits.”
The usual indication for ciprofloxacin is a child with infections caused by Pseudomonas or other highly resistant bacteria, Dr. Williams said. “These urinary tract infections usually occur in children with chronic, recurrent UTI due to either urinary reflux or structural abnormalities of the urinary tract.”
“I would consider joint problems as a potential adverse effect to be discussed with the patient and their family and watched for, like any other potential side effect,” said Dr. Williams, who does not have a conflict of interest regarding Cipro or Bayer Pharmaceuticals Corp.
COPYRIGHT 2004 International Medical News Group
COPYRIGHT 2008 Gale, Cengage Learning

Related Results

Advancis Pharmaceuticals acquires KeflexKeflex 750-mg tabletsFDA approval for new strengths of KeflexTips on Keflex-responsive MRSA lesionKeflex-responsive MRSA skin lesions: solving the paradox

Examples of cephalosporins are cefaclor (Ceclor), cefadroxil (Duricef), cefazolin (Ancef, Kefzol, Zolicef), cefixime, (Suprax), cefoxitin (Mefoxin), cefprozil (Cefzil), ceftazidime (Ceptaz, Fortaz, Tazicef, Tazideme), cefuroxime (Ceftin) and cephalexin (Keflex). These medicines are available only with a physician's prescription. They are sold in tablet, capsule, liquid, and injectable forms.
Cephalosporins are sometimes referred to as first, second, and third generation. Each “generation” is effective against more types of bacteria than the one before it. In addition, each subsequent generation is better at getting into the central nervous system (the brain and spinal cord).
Cephalosporins are chemically similar to penicillins, and to other types of antibiotics called cephamycins.
Recommended dosage
The recommended dosage depends on the type of cephalosporin. The physician who prescribed the drug or the pharmacist who filled the prescription should be consulted for the correct dosage.
The following recommendations do not apply when cephalosporins are given as a single intravenous dose prior to or during surgery. The recommendations should be considered if the drugs are used afterwards to treat a surgical infection, particularly if the cephalosporins are given by mouth.
Cephalosporins should be taken exactly as directed by the physician. The patient should never take larger, smaller, more frequent, or less frequent doses than prescribed. The drug should be taken for exactly as long as directed. No doses of the drug should be saved to take for future infections, because the medicine may not be right for other kinds of infections, even if the symptoms are the same. In addition, all of the medicine should be taken to treat the infection for which it was prescribed. The infection may not clear up completely if too little medicine is taken. Taking this medicine for too long, on the other hand, may open the door to new infections that do not respond to the drug.
Some cephalosporins work best when taken on an empty stomach. Others should be taken after meals. The physician who prescribed the medicine or the pharmacist who filled the prescription should give instructions as to how to take the medicine.
When given for surgical prophylaxis, it used to be common practice to give a dose of a cephalosporin as soon as the patient has been called to the operating room . More recently, the practice has been to give a single dose during the surgical procedure. This works just as well as the “on call” dose, and lowers the amount of antibiotic that the patient must take.
Precautions
The following recommendations do not apply when cephalosporins are given as a single intravenous dose prior to or during surgery. They should be considered if the drugs are used afterwards to treat a surgical infection, particularly if the cephalosporins are given by mouth.
Certain cephalosporins should not be combined with alcohol or with medicines that contain alcohol. Abdominal or stomach cramps, nausea, vomiting, facial flushing, and other symptoms may result within 15–30 minutes and may last for several hours. Alcoholic beverages as well as other medicines that contain alcohol should be avoided while being treated with cephalosporins and for several days after treatment ends.
Special conditions
People with certain medical conditions or who are taking certain other medicines can have problems if they take cephalosporins. Before taking these drugs, be sure to let the physician know about any of these conditions:
ALLERGIES. Severe allergic reactions to this medicine may occur. Anyone who is allergic to cephalosporins of any kind should not take other cephalosporins. Anyone who is allergic to penicillin should check with a physician before taking any cephalosporin. The physician should also be told about any allergies to foods, dyes, preservatives, or other substances. The type of allergic reaction should be discussed in detail, since some people have reactions to a drug that are not truly allergies. These people may be able to take cephalosporins safely.
DIABETES. Some cephalosporins may cause false positive results on urine sugar tests for diabetes. People with diabetes should check with their physicians to see if they need to adjust their medication or their diets.
PHENYLKETONURIA. Oral suspensions of cefprozil contain phenylalanine. People with phenylketonuria (PKU) should consult a physician before taking this medicine.

Related Results

Trust, E-innovation and Leadership in ChangeForeign Banks in United States Since World War II: A Useful FringeBuilding Your Brand With Brand Line ExtensionsThe Impact of the Structure of Debt on Target GainsProject Management Standard Program

And when Jones managed a Wal-Mart pharmacy in Springdale, Ark., she once filled a prescription for cephalosporin for a little girl who was allergic to penicillin. While cephalosporin belongs to a different class of antibiotics, Jones warned the girl’s mother that the child could be sensitive to both drugs. The girl did indeed have a reaction, but as the mother gratefully told Jones afterward, the pharmacist’s warning had left the family prepared for it.
COPYRIGHT 2004 Racher Press, Inc.
COPYRIGHT 2008 Gale, Cengage Learning

Related Results

Zithromax clearedZithromax settlementPanel supports Pfizer’s ZithromaxPfizer agrees to modify marketing for ZithromaxAttorneys General announce settlement with Pfizer over Zithromax advertising.

The preservative-free product is being made available in 500-mg vials, each of which will include a bar code and latex-flee vial stopper.
Other companies receiving generic drug product approvals include:
* Apotex Corp. It has been given clearance for zonisamide capsules in 25-, 50- and 100-mg strengths. Available in 100-count bottles, the product is the generic equivalent to Zonegran and is used to treat epilepsy. Barr Pharmaceuticals Inc. and Mylan Laboratories Inc. have also won approval for generic versions of the Eisai Inc. drug.
* Caraco Pharmaceutical Laboratories Ltd. The company will launch tramadol hydrochloride with acetaminophen tablets. The product is the generic equivalent of Ortho-McNeil Pharmaceutical Inc.’s Ultracet brand, indicated for the short-term management of acute pain. Detroit-based Caraco has also been given approval for carbamazepine tablets USP. The product is the generic equivalent of Tegretol, Novartis Pharmaceutical Corp.’s anticonvulsant.
* Ivax Corp. It has received approval of its ANDA for 200-mg doses of clozapine. The product is the generic equivalent to Novartis’ Clozaril, a schizophrenia treatment.
* Par Pharmaceutical Cos. It has been given clearance for cefprozil tablets, the generic version of Bristol-Myers Squibb Co.’s Cefzil. The product is a broad-spectrum cephalosporin antibiotic. The company has also begun shipping doxycycline monohydrate tablets, an authorized generic version of Adoxa, licensed from Bradley Pharmaceuticals Inc.
* Teva Pharmaceuticals USA. The company has debuted oxycodone hydrochloride extended-release tablets, CII, in 10-, 20- and 40-mg strengths. The product is bioequivalent to Oxy-Contin tablets, which are marketed by Purdue Pharma LP. Teva has also rolled out ribavirin tablets. Available in a 200-mg strength, the product is AB-rated to Hoffmann-La Roche Inc.’s Copegus.
COPYRIGHT 2006 Racher Press, Inc.
COPYRIGHT 2008 Gale, Cengage Learning

Contact: Frank Perier, Jr.

Senior Vice President - Finance and Chief Financial Officer

Forest Laboratories, Inc.

909 Third Avenue

New York, New York 10022

212-224-6611

Frank.Perier@frx.com

FOREST LABORATORIES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF INCOME

(Unaudited)

THREE MONTHS ENDED

JUNE 30,

(In thousands,

except per share amounts)

2008 2007

Revenues:

Net sales $893,745 $842,616

Contract revenue 54,153 53,377

Interest income 18,230 26,738

Other income 716 5,543

966,844 928,274

Costs and expenses:

Cost of goods sold 197,340 186,240

Selling, general and administrative 342,955 261,328

Research and development 112,112 136,908

652,407 584,476

Income before income tax expense 314,437 343,798

Income tax expense 71,517 75,636

Net income $242,920 $268,162

Net income per share:

Basic $0.79 $0.84

Diluted $0.79 $0.83

Weighted average number of shares outstanding:

Basic 307,043 319,580

Diluted 307,912 321,921

CONTACT: Frank Perier, Jr., Senior Vice President - Finance and ChiefFinancial Officer, Forest Laboratories, Inc., 1-212-224-6611, Frank.Perier@frx.com
Web site: http://www.frx.com/
Ticker Symbol: (NYSE:FRX)
Terms and conditions of use apply
Copyright 2008 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

How should I take Generic Amoxil amoxicillin?
Take Amoxil amoxicillin exactly as directed by your doctor. If you do not understand these instructions, ask your pharmacist, nurse, or doctor to explain them to you.
Amoxicillin should be taken at evenly spaced intervals throughout the day and night to keep the level in the blood high enough to treat the infection. Follow your doctor’s instructions.
Amoxicillin can be taken with food or without food.
Swallow each regular oral dose (nonchewable tablets and capsules) whole, with a full glass of water.
Chew the chewable tablets thoroughly before swallowing.
Store the tablets and capsules at room temperature and store the suspension in the refrigerator for longer use.
What happens if I miss a dose?
Take the missed dose as soon as you remember, and take the rest of the day’s doses at evenly spaced intervals. However, if it is almost time for the next regularly scheduled dose, skip the dose you missed and take the rest of the doses for the day as directed. Do not take a double dose of this medication unless otherwise directed by your doctor.
What happens if I overdose?
Seek emergency medical attention if an overdose is suspected.
Symptoms of an amoxicillin overdose may include muscle spasms or weakness, pain or twitching, pain in the fingers or toes, loss of feeling in the fingers or toes, seizures, confusion, coma, or agitation.
What should I avoid while taking amoxicillin?
There are no restrictions on food, beverages, or activity during treatment with Amoxil amoxicillin unless otherwise directed by your doctor.
What are the possible side effects of Generic Amoxil amoxicillin?
Contact your doctor immediately if you experience severe or bloody diarrhea and abdominal cramps during treatment with amoxicillin.
If you experience any of the following serious side effects, stop taking Amoxil amoxicillin and seek emergency medical attention or contact your doctor immediately:
an allergic reaction (shortness of breath; closing of the throat; hives; swelling of the lips, face, or tongue; rash; or fainting);
seizures; or
unusual bleeding or bruising.
Other, less serious side effects may be more likely to occur. Continue to take Amoxil amoxicillin and talk to your doctor if you experience
mild nausea, vomiting, diarrhea, or abdominal pain;
white patches on the tongue (thrush/ yeast infection);
itching or discharge of the vagina (vaginal yeast infection);
black, “hairy” tongue or sore mouth or tongue.
Side effects other than those listed here may also occur. Talk to your doctor about any side effect that seems unusual or that is especially bothersome.
What drug(s) may interact with amoxicillin?
allopurinol
birth control pills
methotrexate
neomycin
probenecid
What is the shelf life of the pills?
The expiry date is mentioned on each blister. It is different for different batches. The shelf life is 2 years from the date of manufacture and would differ from batch to batch depending on when they were manufactured.
You can buy Rx Generic Amoxil amoxicillin antibiotics medication at a online pharmacy at cheap prices.

The FDA has indicated that they cannot approve the NDA for ceftobiprole at this time. They have asked J&JPRD to conduct additional audit work of clinical investigator sites and to address specific questions related to site monitoring.

J&JPRD and its co-development partner, Swiss-based Basilea Pharmaceutica Ltd., are reviewing the Complete Response letter and will continue to work with the FDA to resolve questions that are outlined in the Complete Response letter.

The NDA for ceftobiprole was submitted to the FDA in May 2007, and, in March 2008, J&JPRD received an Approvable Letter regarding the ceftobiprole filing. J&JPRD responded to the FDA’s Approvable Letter in August 2008.

Ceftobiprole was approved earlier this year in Canada, and most recently it was approved in Switzerland. Last week, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency recommended approval of ceftobiprole in the European Union for the treatment of complicated skin and soft tissue infections.

Ceftobiprole is a novel, broad-spectrum, anti-MRSA cephalosporin with activity against methicillin-resistant (MRSA), penicillin-resistant and many clinically important Gram-negative bacteria, including .

MRSA is a type of bacteria that is resistant to certain antibiotics. These antibiotics include methicillin and other more common antibiotics such as oxacillin, penicillin and amoxicillin. Staphylococcal (frequently called “Staph”) infections, including MRSA, previously occurred most frequently among persons in hospitals and healthcare facilities who have weakened immune systems. Increasingly, cases are being reported in outpatient and community settings. These cases are referred to as community-associated MRSA (CA-MRSA) and are a growing healthcare concern.

J&JPRD is part of Johnson & Johnson, the world’s most broadly based producer of healthcare products. J&JPRD is headquartered in Raritan, NJ, and has facilities throughout Asia, Europe and the United States. J&JPRD is leveraging drug discovery and drug development in a variety of therapeutic areas to address unmet medical needs worldwide.
[This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Johnson & Johnson's expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of the Company's Annual Report on Form 10-K for the fiscal year ended December 30, 2007. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.]

CONTACTS:
Media: Greg Panico, 908-927-3715 (office) or 908-240-2011 (cell)
Investor Relations: Stan Panasewicz, 732-524-2524 or Tina Pinto,
732-524-2034

CONTACT: Media: Greg Panico, 1-908-927-3715 (office), or 1-908-240-2011(cell); Investor Relations: Stan Panasewicz, 1-732-524-2524 or Tina Pinto,1-732-524-2034
Web site: http://www.jnj.com/
Terms and conditions of use apply
Copyright 2008 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Erysipelas may affect both children and adults. The risk factors associated with this infection include a cut in the skin, skin ulcers, and problems with the drainage through the veins or lymph system. In the past, the face was most commonly involved site of infection, yet now accounts for only up to 20% of cases. The legs are affected in up to 80% of cases.

The most common complaints during the acute infection include tenderness of the involved area, fever, chills, and swelling. Death as a direct result of erysipelas is exceedingly rare. Predisposed patients often develop local recurrence, and this can lead to disfiguring and disabling healing reactions, such as elephantiasis nostras verrucosa. This chronic warty, edematous condition is caused by lymphatic destruction from repeated infection.

Erysipelas is most often caused by a specific Streptococcus bacteria known as Group A Streptococcus. In a few cases, it can be caused by other types of Streptococcus or Staphylococcus bacteria. Some cases of erysipelas have an inciting wound such as trauma, an abrasion, or some other break in the skin that precede the fiery infection. However, in most cases, no break in the skin can be found.

Erysipelas predominantly affects the skin of the lower limbs, but when it involves the face it can have a characteristic butterfly distribution on the cheeks and bridge of the nose. Symptoms and signs of erysipelas are usually abrupt in onset and often accompanied by general illness in the form of fevers, chills and shivering. Affected skin is distinguished from other forms of cellulitis by a well-defined, raised border. The affected skin is red, swollen and may be finely dimpled (like an orange skin). It may be blistered. Bleeding into the skin may cause purpura (purple patches). Cellulitis does not usually exhibit such marked swelling but shares other features with erysipelas such as pain and increased warmth of affected skin.

In adults, Group A streptococcal bacterial infection is the most common cause and in children Hemophilus influenza bacterial infection is the most common cause. Treatment for adults is with antibiotics usually a penicillinase resistant penicillin, cephalosporin, or erythromycin IV or oral depending on the sensitivity. For children less than 3 years old prompt treatment with IV cephalosporins i.e. ceftriaxone is indicated.

infection of the skin and underlying tissue, caused by group A B-hemolytic streptococcus bacteria. Erysipelas causes affected areas of skin to turn bright red and become slightly swollen. The swollen blotches have a distinct border and slowly expand into the surrounding skin. The lesions are most commonly seen on the face, scalp, hands, and legs.

Patients typically develop symptoms including high fevers, shaking, chills, fatigue, headaches, vomiting, and general illness within 48 hours of the initial infection. The erythematous skin lesion enlarges rapidly and has a sharply demarcated raised edge. It appears as a red, swollen, warm, hardened and painful rash, similar in consistency to an orange peel. More severe infections can result in vesicles, bullae, and petechiae, with possible skin necrosis. Lymph nodes may be swollen, and lymphedema may occur. Occasionally, a red streak extending to the lymph node can be seen.